The left atrial appendage is the forward protruding part of the right front of the left atrium and is a tissue structure closely related to atrial fibrillation. The thrombus formed in the left atrial appendage is easy to fall off, and will move with the blood flow to the brain, kidneys and other parts to form embolism, which has a high disability and mortality rate. Left atrial appendage occlusion is to fix the occluder in the left atrial appendage to prevent the thrombus that may form in the left atrial appendage from falling off during atrial fibrillation. The left atrial appendage occlusion device is a medical device used in left atrial appendage occlusion surgery for patients with atrial fibrillation.
According to the new market research report "Left Atrial Appendage Occluders - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030", published by QYResearch, the global Left Atrial Appendage Occluder market size is projected to grow from USD 12.7 billion in 2023 to USD 49.4 Billion by 2029, at a CAGR of 21.4% during the forecast period.
- Global Left Atrial Appendage Occluder MarketSize(US$ Billion), 2018-2029
Source: QYResearch, "Left Atrial Appendage Occluders - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030”
- Global Left Atrial Appendage Occluder Top9Players Ranking and Market Share（Continually updated）
Source: QYResearch, "Left Atrial Appendage Occluders - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030”
Globally, major manufacturers of left atrial appendage occlusion devices include Boston Scientific, Abbott, Occlutech, Atircure, J&J, etc., with the top five manufacturers accounting for approximately 95.94% of the market share.
Since the left atrial appendage occluder has a specific location and morphological characteristics, there are extremely high requirements for its development and production. It was not until 2002 that the first left atrial appendage occluding device "PLATO" appeared on the global market. Unfortunately, the development of this occluding device was later terminated due to complications and funding issues. The company that has truly realized the global promotion and application of left atrial appendage occlusion devices is Boston Scientific, whose WATCHMAN left atrial appendage occlusion device is now the “gold standard” of left atrial appendage occlusion devices. In 2006, the WATCHMAN left atrial appendage occlusion device obtained CE certification and entered the European market; in 2009, Europe and Australia took the lead in carrying out WATCHMAN left atrial appendage occlusion treatment, with Germany having an annual implantation volume of up to 3,000 cases; the United States started late, in March 2015 The WATCHMAN left atrial appendage occlusion device has just been approved by the FDA, and currently the number of implants annually reaches over 10,000.
Major left atrial appendage occlusion device companies include:
Boston Scientific: Boston Scientific is the world's leading medical device company. Its Watchman® left atrial appendage occlusion device is the world's first approved left atrial appendage occlusion device, which has the advantages of high safety and strong effectiveness.
Abbott: Abbott is the world's leading healthcare company. Its Amulet® left atrial appendage occlusion device is the world's first fully recyclable and releasable left atrial appendage occlusion device. It has the advantages of high flexibility and adaptability.
Occlutech: Occlutech is a leading provider of minimally invasive cardiac implants for the treatment of structural heart disease. Founded in 2003, the company is headquartered in Istanbul, Turkey, with manufacturing facilities in Germany and Switzerland. Occlutech® occluders are made of self-expanding nitinol mesh covered with a thin biocompatible fabric. It is inserted through a catheter inserted into a blood vessel (usually in the groin) and placed over the opening of the left atrial appendage. The nitinol mesh expands to fit the shape of the left atrial appendage, and the fabric seals the opening, preventing blood clots from forming inside.
AtriCure: AtriCure is a medical device company developing innovative technologies to treat atrial fibrillation (AFib) and related conditions. Founded in 1997, the company has become a global leader in its field, delivering solutions that improve the lives of patients around the world. Its AtriClip® left atrial appendage occlusion device is the world's first transfemoral vein transcatheter implantable left atrial appendage occlusion device.
The United States is currently a relatively mature market for left atrial appendage occlusion devices, which are covered by medical insurance and have more than 30,000 implants annually. The market structure is clear, with only two companies, Abbott and Boston Scientific, competing. The United States is one of the countries with the most developed medical technology in the world and is highly receptive to new technologies. In addition, the large number of atrial fibrillation patients in the United States provides huge potential for the left atrial appendage occluder market. North America accounts for approximately 50% of the global market share.
Europe is the second largest region in the global left atrial appendage occluder market. Europe accounts for about 25% of the global market share. Europe's medical technology level is relatively high, and its acceptance of new technologies is also relatively high. In addition, the number of patients with atrial fibrillation is increasing in Europe.
In the next few years, the Asia-Pacific region will become the fastest growing region in the global left atrial appendage occluder market. The market size of left atrial appendage occluders in the Asia-Pacific region accounts for about 22% of the global market share. The Asia-Pacific region has a large population and an obvious aging trend, and the number of patients with atrial fibrillation is also increasing. In addition, the level of medical technology in the Asia-Pacific region is also constantly improving, and the acceptance of new technologies is also increasing.
Market Drivers:
Rising Prevalence of Atrial Fibrillation (AF): AF is the most common type of irregular heartbeat, affecting millions of people worldwide. It is a major risk factor for stroke, and the LAAO device offers a minimally invasive alternative to blood thinners for stroke prevention in certain AF patients.
Technological Advancements: LAAO devices have undergone continuous innovation, with newer models offering improved safety, efficacy, and ease of implantation. This has led to wider adoption by physicians and increased patient confidence in the technology.
Improved Reimbursement Coverage: Insurance companies are increasingly recognizing the cost-effectiveness of LAAO devices compared to long-term blood thinner therapy. This is leading to wider reimbursement coverage, making the procedure more accessible to patients.
Untapped Market Potential: The LAAO market is still in its early stages of growth, with significant potential in emerging economies like China and India, where the prevalence of AF is high and access to advanced healthcare is improving.
Restraint:
High Cost and Limited Reimbursement: The LAAO procedure itself is expensive, and the devices add to the cost burden. While some insurance companies are increasingly covering the procedure, it's not universally covered, potentially limiting patient access.
Procedural Complexity and Physician Expertise: Implanting an LAAO requires specialized skills and training. The limited number of trained physicians could hinder wider adoption, especially in regions with less developed healthcare infrastructure.
Lack of Long-Term Data: While short-term studies show promising results, long-term data on the safety and efficacy of LAAO devices compared to other stroke prevention methods is still limited. This could raise concerns among some physicians and patients.
Potential Complications and Device-Related Issues: Like any medical procedure, LAAO carries potential risks like device dislodgement, perforation, and pericardial effusion. Addressing these concerns and improving device safety is crucial for wider adoption.
About QYResearch
QYResearch founded in California, USA in 2007.It is a leading global market research and consulting company. With over 16 years’ experience and professional research team in various cities over the world QY Research focuses on management consulting, database and seminar services, IPO consulting, industry chain research and customized research to help our clients in providing non-linear revenue model and make them successful. We are globally recognized for our expansive portfolio of services, good corporate citizenship, and our strong commitment to sustainability. Up to now, we have cooperated with more than 60,000 clients across five continents. Let’s work closely with you and build a bold and better future.
QYResearch is a world-renowned large-scale consulting company. The industry covers various high-tech industry chain market segments, spanning the semiconductor industry chain (semiconductor equipment and parts, semiconductor materials, ICs, Foundry, packaging and testing, discrete devices, sensors, optoelectronic devices), photovoltaic industry chain (equipment, cells, modules, auxiliary material brackets, inverters, power station terminals), new energy automobile industry chain (batteries and materials, auto parts, batteries, motors, electronic control, automotive semiconductors, etc.), communication industry chain (communication system equipment, terminal equipment, electronic components, RF front-end, optical modules, 4G/5G/6G, broadband, IoT, digital economy, AI), advanced materials industry Chain (metal materials, polymer materials, ceramic materials, nano materials, etc.), machinery manufacturing industry chain (CNC machine tools, construction machinery, electrical machinery, 3C automation, industrial robots, lasers, industrial control, drones), food, beverages and pharmaceuticals, medical equipment, agriculture, etc.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
Email: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp